Posted: Monday, October 3, 2022
Cytokine-release syndrome and neurologic events do not seem to be associated with any long-term detriment in overall health-related quality of life in patients with relapsed or refractory large B-cell lymphoma (LBCL) who respond to chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel, according to Donald Patrick, PhD, MSPH, of the University of Washington, Seattle, and colleagues. Their analysis of quality-of-life data collected from the TRANSCEND NHL 001 study supports earlier anecdotal findings. These results were presented during the 2022 American Society of Clinical Oncology (ASCO) Quality Care Symposium (Abstract 294).
In TRANSCEND, the incidence of all-grade cytokine-release syndrome and neurologic events was 42% and 30%, respectively, among the 137 patients who responded to lisocabtagene maraleucel in the third line or later. For this analysis, the patients were stratified into three groups: (1) those who had no cytokine-release syndrome or neurologic events; (2) those who had either cytokine-release syndrome or neurologic events but not both; and (3) those who had both cytokine-release syndrome and neurologic events. The researchers evaluated health-related quality of life with the European Organisation for Research and Treatment of Cancer QLQ-C30 and the EuroQol 5D-5L tool.
In subgroups 2 and 3, “clinically relevant QLQ-C30 functional (physical, role, and cognitive) and fatigue scores indicated a noticeable nadir around 1 month after [lisocabtagene maraleucel] infusion, followed by a trend toward restoration of baseline status, generally achieved by 2 months after baseline,” reported Dr. Patrick and co-investigators. “The primary difference [between subgroups 2 and 3] appeared to be the extent of decline or depth of the nadir.” Patients in the first subgroup did not experience an initial decrease in health-related quality of life and instead showed a trend toward improvement over time.
Disclosure: The study authors’ disclosure information can be found at coi.asco.org.